(+)-VINCRISTINE
Recurrent T Lymphoblastic Lymphoma
National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
45 Active assets in the Recurrent T Lymphoblastic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | BB |
METHOTREXATE Children's Oncology Group | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
ASPARAGINASE University of Washington | Phase 3 | BB |
Cyclophosphamide Children's Oncology Group | Phase 3 | BB |
View all 50 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →